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Abstract
Background: Bacillus Calmette-Guerin (BCG) is the most effective treatment for non-muscle invasive bladder cancer.
However, a failure in the initial response or relapse within the first five years of treatment has been observed in 20% of
patients. We have previously observed that in vivo administration of an inhibitor of nitric oxide improved the response to
BCG of bladder tumor bearing mice. It was described that this effect was due to a replacement of tumor tissue by collagen
depots. The aim of the present work was to clarify the mechanism involved in this process.
Methodology/Principal Findings: We demonstrated that BCG induces NIH-3T3 fibroblast proliferation by activating the
MAPK and PI3K signaling pathways and also differentiation determined by alpha-smooth muscle actin (alpha-SMA)
expression. In vivo, intratumoral inoculation of BCG also increased alpha-SMA and collagen expression. Oral administration
of L-NAME enhanced the pro-fibrotic effect of BCG. Peritoneal macrophages obtained from MB49 tumor-bearing mice
treated in vivo with combined treatment of BCG with L-NAME also enhanced fibroblast proliferation. We observed that FGF-
2 is one of the factors released by BCG-activated macrophages that is able to induce fibroblast proliferation. The
involvement of FGF-2 was evidenced using an anti-FGF2 antibody. At the same time, this macrophage population improved
wound healing rate in normal mice and FGF-2 expression was also increased in these wounds.
Conclusions/Significance: Our findings suggest that fibroblasts are targeted by BCG both directly and through activated
macrophages in an immunotherapy context of a bladder murine model. We also described, for the first time, that FGF-2 is
involved in a dialog between fibroblasts and macrophages induced after BCG treatment. The fact that L-NAME
administration improves the BCG effect on fibroblasts, NO inhibition, might represent a new approach to add to the
conventional BCG therapy.
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Introduction
At the time of diagnosis, 60–80% of bladder tumors are non-
muscle invasive and confined to the urothelium and/or lamina
propria. These include papillary tumors or carcinoma in situ. Both
types of tumors commonly occur concurrently. In 1976, Morales
et al. [1] reported, for the first time, the successful intravesical use of
Bacillus Calmette Guerin (BCG) as an adjuvant treatment for non-
muscle invasive bladder cancer following transurethral resection. It
isnowwidelyacceptedthatintravesicalBCGismorepotenttherapy
in preventing tumor recurrence than any intravesical chemotherapy
[2]. However, about 20% of patients either fail to respond initially
or relapse within the first five years of treatment [3].
It is known that BCG generates a local immunological reaction
with activation of immune cells as well as secretion of cytokines
involving Th1 cell cytotoxicity [4]. A significant increase in
polymorphonuclear and mononuclear cell that infiltrate in bladder
tumors after BCG therapy has been observed [5]. Since
macrophages (MACs) are phagocytic and antigen presenting cells
and have the capacity to secrete cytokines and growth factors, they
are considered the best equipped cells involved in BCG
immunotherapy. Depending on the microenvironment, the nature
and intensity where MACs differentiation takes place, these cells
are able to activate different pathways and give rise to particular
profiles [6]. The responses of MACs following injury or infection
are examples of many different stimuli that trigger MACs
activation in tissues, displaying great plasticity. BCG, when used
as immunotherapy for bladder tumors, is processed by MACs and
urothelial cells, resulting in the early release of inflammatory
cytokines, some of which may be responsible for certain adverse
effects observed in patients [7,8]. One of the mediators of this
inflammatory process is nitric oxide (NO), generated by a family of
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products usually activate the expression of the inducible NOS
(iNOS) isoform, generating large amounts of NO. iNOS is not
expressed in normal bladder epithelium but has been detected in
early bladder tumor recurrences [9] and it has been reported that
iNOS expression in tumor cells could be associated with
unresponsiveness to BCG [10]. We have previously reported that
in vivo administration of BCG to MB49 tumor bearing mice
decreased tumor growth and that the combined treatment of BCG
with the NOS inhibitor L-NAME significantly improved tumor
regression by replacing tumor tissue by collagen depots, resem-
bling wound healing [11]. Our present results suggest that control
of bladder tumor recurrences by BCG therapy involve stroma
reorganization and that NO inhibition might improve tissue
remodeling. Wound healing is an example of tissue reorganization,
since after wound generation, growth factors released to the
extracellular matrix induces an inflammatory process which allows
cell migration [12]. Among others, MACs and fibroblast are
important cells involved in this process. Fibroblast migrate towards
the damaged zone, differentiate into myofibroblasts and synthesize
extracellular matrix proteins that allow the contraction and finally
the wound close. In a wound healing context, growth factors such
a fibloblast growth factor-2 (FGF-2) and transforming growth
factor beta (TGF-beta) secreted by MACs, stimulate fibroblasts
which are responsible for the synthesis, deposition and remodeling
of the extracellular matrix [13]. FGF-2 was originally identified as
a basic growth factor which stimulates the proliferation of NIH-
3T3 fibroblasts. Besides, several studies have shown a role of FGF-
2 in tissue fibrosis, where this factor is increased in acute wounds
and plays a role in granulation tissue formation, reepithelization
and tissue remodeling [12,14].
To our knowledge, there is no information about the role in
tissue remodeling of the BCG when used in bladder cancer
treatment. Therefore, the aim of our work was to evaluate the
effect of BCG on fibroblast activation, measured by MAPK and
PI3K signaling pathways and collagen I, and alpha-smooth muscle
actin (alpha-SMA) expression. Since MACs are involved in both
BCG response and in tissue reorganization as observed in the
process of wound healing [6,15] we also evaluated the role of
MACs under BCG treatment and NO inhibition therapy, in
fibroblast activation in a wound healing model. Our findings
suggest that, as part of the mechanisms of bladder cancer control,
BCG induces activation of fibroblasts either directly or through
MACs, that by releasing soluble products, can by themselves
activate fibroblasts. The participation of NO as a negative
regulator of this process was also demonstrated.
Results
BCG induces NIH-3T3 proliferation
It has been described that BCG is able to induce cell cycle arrest
and apoptosis in bladder tumor cell lines [15,16]. However, one
remaining question could be what would be the effect of BCG on
fibroblasts? To answer this question NIH-3T3 cells were cultured
under different concentrations of BCG. As shown in Fig. 1A and
1B, BCG induced the proliferation of NIH-3T3 cells, evaluated
both by counting the number of cells and by the MTS assay.
Induction of fibroblast proliferation was detected with BCG
concentrations from 1.5610
6 CFU/ml up to 3610
6 CFU/ml,
diminishing for concentrations higher than 6610
6 CFU/ml. Our
results show discrepancies when the determination of the
proliferation was made either by counting the number of cells or
by MTS (figure 1 A and B respectively) for concentrations equal or
greater than 6610
6 CFU/ml. We think that this difference was
related to enhance of mitochondrial activity induced by high
quantities of BCG. Thus, the following experiments were carried
out with 3610
6 CFU/ml of BCG for which there is agreement
between the two forms of quantification. To evaluate whether
PI3K and MAPK pathways are involved in BCG-induced
fibroblast proliferation, we analyzed the effects of LY 294002
and PD 98059, inhibitors of PI3K and MAPK pathways
respectively, on fibroblast proliferation induced by BCG. We also
evaluated the phosphorylation of ERK and AKT, two activated
molecules that are key in these pathways. We observed that LY
(20 mM) was able to inhibit the proliferation induced by BCG after
24 h of treatment (Fig. 1C), and that PD (50 mM) inhibited the
proliferation induced by BCG after 48 h of treatment (Fig. 1D). As
shown in Fig. 1E and 1F, BCG treatment induced a rapid
phosphorylation of ERK and AKT within 5 min. Western blot
analyses revealed that the phosphorylation of AKT was stimulated
between 5–10 min, decreasing after 20 min (Fig. 1E). BCG also
induced ERK1 and ERK2 phosphorylation after 5 min, which
then diminished after 30 min (Fig. 1F). This interaction between
BCG and fibroblast involves both a proliferation and a survival
pathway. These data suggest that BCG targets not only tumor cells
and MACs, but also fibroblasts.
The proliferation of NHI-3T3 cells was enhanced by L-NAME
from 0.5 to 4 mM (p,0.05) in a concentration-independent
manner (data not shown). When fibroblasts were treated with a
combined protocol, the highest proliferation activity was detected
with BCG 3610
6 CFU/ml plus L-NAME 2mM (Fig 2). This
effect was inhibited by LY 294002 and PD 98059, thus indicating
that L-NAME is able to improve BCG-induced proliferation in
NIH-3T3 cells mediated by MAPK and PI3K signaling pathways.
BCG induces NIH-3T3 differentiation
Activation of fibroblasts into myofibroblasts, a crucial step in the
process of wound healing, is characterized by the development of
intracytoplasmic stress fibers that confer to these cells the capacity
of developing tension, and by the increased synthesis of
extracellular matrix components, such as collagen type I [17,18].
The most important marker of the fibroblast/myofibroblast
phenotypic transition is the novo expresio ´n of alpha-smooth
muscle actin [19]. So, we analyzed alpha-SMA and collagen I as
indicators of fibrogenic activity and evaluated the expression of
these molecules in NIH-3T3 cells treated with BCG.
To establish the best dose of BCG, immunofluorescence of both
proteins was carried out in fibroblasts treated with different
concentrations of BCG for 24 h (data not shown). The strongest
expression of both alpha-SMA and collagen I was observed with
3610
6 CFU/ml of BCG (Fig. 3A), thus, this concentration was
chosen to carry out the Western blots analyses. Figure 3B shows
that 3610
6 CFU/ml of BCG was able to induce collagen I
expression after 6 h of treatment, being the expression 2.5-fold
higher than controls after 12 h of treatment. A significant
induction of alpha-SMA after 12 h of BCG treatment was
observed, remaining increased at 48 h post treatment. Taken
together the data showed up to now, we could hypothesize that
fibroblast activation can also take place in vivo.
BCG induces fibroblast activation through macrophages
in vitro and induces collagen and alpha-SMA expression
in MB49 tumors in vivo
As the direct treatment with BCG induces fibroblast prolifer-
ation and MACs are some of the most important cells in BCG
responses, we hypothesized that there is a dialog between
fibroblasts and MACs under BCG treatment. In order to test
BCG and Fibroblast Activation
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the proliferation and differentiation of fibroblasts. First, we
evaluated NO production in MACs treated with BCG. As shown
in Fig. 4A, peritoneal MACs from tumor-bearing mice treated in
vivo with BCG produced higher amounts of NO than those from
non-treated ones. In vitro, the treatment of the MACs cell line
RAW 264.7 with BCG also increased NO production. To evaluate
the role of the soluble products released from MACs, we obtained
the conditioned media (CM) from peritoneal MACs from tumor-
bearing mice either treated in vivo or not with BCG +/2 L-
NAME. We observed that CM from peritoneal MACs from
tumor-bearing mice (MACs-T) of the different groups induced
fibroblast proliferation. Particularly, the CM of MACs from
tumor-bearing mice treated in vivo with BCG (MACs-T-BCG)
plus L-NAME induced the highest fibroblasts proliferation rate in
vitro. The CM from untreated RAW 264.7 did not modify
fibroblast proliferation. However, the in vitro treatment of RAW
264.7 with BCG either combined or not with L-NAME, similarly
to peritoneal MACs, also induced NIH-3T3 proliferation (Fig. 4B).
The CM obtained from RAW 264.7 induced collagen I
expression in fibroblasts. The expression was higher when the
CM was from MACs treated with BCG, and this effect was
Figure 1. BCG induces fibroblast proliferation. (A) NIH-3T3 fibroblast were treated with different concentration of BCG for 24 h. Cells were
counted or (B) cell viability was evaluated by a non-radioactive cell titter method (MTS), vs control: p,0.05. (C) Effect of LY 294002 and (D) PD 98059
evaluated by MTS in fibroblast stimulated with BCG (3610
6 CFU/ml) for 24 and 48 h respectively, a: p,0.05 vs control, b: vs BCG. Fibroblast
stimulated with BCG (3610
6 CFU/ml) and p-AKT (E) and p-ERK (F) determined by Western blot. Relative phosphorylation levels were normalized to
total protein and referred as a fold change of control, a: p,0.05.
doi:10.1371/journal.pone.0013571.g001
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RAW 264.7 treated with BCG plus L-NAME also induced alpha-
SMA expression (Fig. 4C). These results seem to indicate that
there are some soluble factors secreted from MACs activated by
BCG which can induce fibroblast proliferation and activation.
With the aim to evaluate this effect in vivo we analyzed collagen
deposition and alpha-SMA expression in MB49 tumor-bearing
mice under BCG and L-NAME treatment. Our results showed
that both BCG and L-NAME and their combination induced the
deposition of collagen fibers in these tumors. BCG and L-NAME
also induced expression of alpha-SMA compared with the control
group. However, more intense staining of alpha-SMA was
observed in tumors treated with BCG plus L-NAME. These
results suggest that BCG may induce the activation of fibroblasts in
vivo, and that this effect is enhanced by inhibition of NO
production.
Nitric oxide inhibition improves in vivo wound healing
induced by peritoneal MACs from tumor-bearing mice
treated with BCG
To determine the functional capacity of MACs under BCG
treatment and its regulation by NO, an in vivo experiment of
wound healing was performed. Peritoneal MACs–T either treated
or not with BCG in vivo were placed in a dorsal skin wound of
normal mice. The NO inhibitors L-NAME and 1400W were
added in wounds either alone or combined with MACs. The
surface wound was significantly diminished when the MACs from
normal (data not shown) or MACs-T were added on the wound as
compared with the controls, where only PBS-glycerol solution was
added. It is important to note that the addition of the NO
inhibitors L-NAME or 1400W alone were able to significantly
diminish the surface wound. When peritoneal MACs from tumor-
bearing mice which had received BCG intratumorally (MACs-T-
BCG) were added on the wound, the percentage of wound closure
was diminished, as compared with the wounds with MACs-T.
However, when these MACs-T-BCG were added with 1400 W,
the wound healing rate was significantly increased (Fig. 5A).
When the dorsal skin wound was generated in mice drinking the
NO inhibitor L-NAME, the surface wound was diminished
compared with the control group. MACs-T-BCG addition also
induced the acceleration of wound repair. Besides, MACs-T-BCG
addition improved the wound repair when mice received L-
NAME orally (Fig. 5B).
FGF-2 mediates the stimulatory effect of BCG-activated
macrophages on fibroblasts
It has been demonstrated that FGF-2 is one of the main growth
factors involved in fibroblast proliferation [20]. Besides, it has been
shown that FGF-2 is able to inhibit apoptosis in NIH-3T3 cells
Figure 2. L-NAME improves BCG-induced proliferation. NIH-3T3
fibroblast were treated with BCG (3610
6 CFU/ml), L-NAME (2 mM) or
BCG and L-NAME in presence of LY 294002 and PD 98059 for 24 and
48 h respectively. Cell viability was evaluated by MTS. a: p,0.01 vs
Control; b: p,0.05 vs BCG or L-NAME alone; c:p,0.01 vs their
respective Control.
doi:10.1371/journal.pone.0013571.g002
Figure 3. BCG induces fibroblast differentiation. (A) Immuno-
fluoresce staining of NIH-3T3 treated with BCG (3610
6 CFU/ml) for 24 h
revealed with anti-collagen I and anti-alpha-SMA antibody. Scale:
bar=100 um. (B) Western Blot from fibroblast homogenates treated
with BCG (3610
6 CFU/ml) at different times to determinate collagen I
and alpha-SMA induction. (C) Densitometric units of collagen I or (D)
alpha-SMA were determined using analysis software, relativized to beta-
actin and referred as a fold change of control a: p,0.05, b: p,0.01.
doi:10.1371/journal.pone.0013571.g003
BCG and Fibroblast Activation
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peritoneal MACs from MB49 tumor bearing mice (MACs-T) and RAW 264.7 cells treated in vivo with BCG (6610
6 CFU/ml) or in vitro (3610
6 CFU/ml)
respectively, were evaluated in the supernatant by Griess reagent. a: p,0.0001 vs control. RAW 264.7 cells were treated with BCG (3610
6 CFU/ml) for
24 h, and then cells were extensively washed with PBS. Serum-free medium was added and incubation was continued for 24 hours to obtain the CM.
(B) fibroblast treated for 48 h with the CM from peritoneal or RAW 264.7 cells previously treated with BCG (3610
6 CFU/ml) plus L-NAME (2 mM).
Fibroblast viability was evaluated by MTS and referred as a percentage of control (RAW 264.7 or NIH-3T3 untreated cell lines), a: p,0.05 and b:
p,0.01 vs control, c: p,0.05 vs MACs-T control. (C) Western Blot to determine collagen I and alpha-SMA from fibroblast homogenates treated for
24 h with CM from RAW 264.7 previously treated for 24 h with BCG plus L-NAME. Relative expression level was normalized to beta-actin and referred
as a fold change of control, a: p,0.05, b: p,0.01. (D) Masson Trichome (top panel) and immunohistochemical staining (bottom panel), to determine
BCG and Fibroblast Activation
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sized that FGF-2 could be one of the soluble factors secreted by
activated MACs able to stimulate the proliferation of fibroblasts.
To confirm this idea, we first analyzed whether FGF-2 is
modulated in MACs RAW 264.7 cells under BCG treatment.
Figure 6A shows, by Immunofluorescence staining, that FGF-2 is
increased in MACs RAW 264.7 treated with BCG compared with
untreated cells. This was also observed by western blot assay
(figure 6B), where it can be seen one band of 17.2 kDa compatibly
with secretory FGF-2. Bands of higher molecular weight represent
non-secretory FGF-2. We then performed a proliferation assay
with CM derived from RAW 264.7 activated by BCG, depleted or
not of FGF-2. CM from RAW 264.7 treated with BCG increased
fibroblast proliferation, while the depletion of FGF-2 significantly
reduced the fibroblast stimulation, suggesting that BCG-activated
MACs could induce fibroblast proliferation, at least in part, by
FGF-2 secretion. Fibroblasts migrate into the wound, where they
proliferate and produce large amounts of extracellular matrix.
Some fibroblasts differentiante into myofibroblasts, which are
responsible for the wound contraction and the deposition of
additional matrix [22]. To evaluate if MACs from tumor bearing
mice treated with BCG are capable to induce FGF-2 in vivo,
expression of FGF-2 was evaluated either in wound healing assays.
Beside, we also evaluated the FGF-2 expression in MB49 tumors.
Histological analyses from skin wounds showed increased
expression of FGF-2 in wounds with MACs-T-BCG. When these
MACs were placed together with NO inhibitors on wounds, the
FGF-2 expression remained high (Fig. 6D). The high level of FGF-
2 was consistent with the increased healing rate that was showed in
Fig. 5. Furthermore, similar results were observed in MB49
tumors, where the expression of FGF-2 was higher in tumors from
mice treated either with BCG or with L-NAME than in controls.
Tumors derived from mice receiving the combined treatment
showed more localized and intensive FGF-2 staining (Fig. 6E). In
this model, our results show that the FGF-2 is associated with
mechanism of action BCG immunotherapy.
Discussion
Intravesical therapy with BCG plays a major role in the
treatment and prophylaxis of recurrent non-muscle invasive
bladder carcinoma [23].
Shelley et al. [24] have recently described in a meta-analyses
study that BCG used as adjuvant after transurethral resection
reduced the risk of recurrence by 67% at 12 months compared to
transurethral resection alone; however, some side effects such as
cystitis, fever and hematuria, were associated with BCG
administration. The exact mechanism of the antitumor activity
of BCG is not completely understood, but it appears that BCG
involves both direct effects on tumor cells [16] and indirect effects
mediated by immune cells [7].
We have previously reported that BCG wass able to induce
growth inhibition of MB49 bladder tumor cells either in vitro or
inoculated vivo into syngeneic mice NO produced by MB49
cancer cells treated with BCG induced MACs and splenocytes
death, thus suggesting an in vivo immunosuppressive function of
NO. Our experiments also showed a greater inhibition of tumor
growth in mice treated with BCG combined with L-NAME
compared to BCG alone. In the first case, few remaining tumor
cells were completely surrounded by collagen fibers [11].
In the present work, we investigate some of the mechanisms by
which BCG and L-NAME generate the scar we described
previously. The MAPK and PI3K signaling pathways have been
widely studied in different models. These are activated by different
stimuli such as growth factors and cytokines [25,26]. Our present
findings demonstrate that BCG is able to directly induce NIH-3T3
Figure 5. NO inhibition increases wound healing closure
generated by peritoneal MACs. (A) Peritoneal MACs from tumor
bearing mice either treated or not with BCG (MACs-T-BCG and MACs-T
respectively), were placed in dorsal skin wound of normal mice. L-NAME
(2 mM) or 1400 W (1 uM) was added onto the wound. The wound
closure was calculated as the percentage of the initial wound area (day
zero), a: p,0.01, b: p,0.001 vs PBS-gli, c: p,0.05 vs MACs-T-BCG
control. (B) Peritoneal MACs-T-BCG were placed in dorsal skin wound of
mice treated orally with L-NAME (0.2 g/kg mouse), a: p,0.0001 vs PBS-
gli, b: p,0.01 vs MAC-T-BCG control.
doi:10.1371/journal.pone.0013571.g005
collagen fibers and alpha-SMA respectively, were performed in MB49 tumors growing subcutaneously in mice treated with BCG, L-NAME or BCG+L-
NAME. White arrows show blue stain of collagen fibers. Yellow arrows show brown positive staining for alpha-SMA. Scale: bar=100 um.
doi:10.1371/journal.pone.0013571.g004
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pathways, collagen expression and fibroblast differentiation as
determined by alpha-SMA expression. Besides, immunohisto-
chemistry of tumors from BCG treated mice, showed increased
expression of collagen fibers and alpha-SMA, suggesting that
fibroblast activation could also take place.
We believe that BCG can act on the stroma surrounding tumor
cells that may remain after tumor resection or on a new rising
Figure 6. FGF-2 secreted by BCG-treated MACs induces NIH-3T3 cells proliferation. (A) Immunofluorescence staining with anti-FGF-2
antibody of RAW 264.7 MACs treated with BCG (3610
6 CFU/ml) for 24 h. (B) Western blot from lysates of RAW 264.7 treated with BCG (3610
6 CFU/
ml) for 8 and 24 h. 20 ng of purified murine FGF-2 was used as a positive control. Relative expression level was normalized to GAPDH and referred as
a fold change of control, a: p,0.05 (C) fibroblasts were treated with CM from RAW 264.7 cells previously treated with BCG (3610
6 CFU/ml), L-NAME
or BCG plus L-NAME for 24 h. Control was carried out with exhausted culture media (CM 3T3, from the same NIH-3T3 cells). 0.5 ng/ml of FGF-2 in CM
3T3 was used as a positive control. NIH-3T3 proliferation was monitored by
3(H) thymidine incorporation. The CM was preincubated 1 h with 10 mg/
ml of the blocking monoclonal anti FGF-2 antibody (DB3), or normal IgG as a control, a: p,0.001 vs CM NIH-3T3, b: p,0.001 vs IgG. (D)
Immunohistochemical staining to determinate FGF-2 expression was performed in skin wounds. Wounds were treated with peritoneal MACs from
tumor bearing mice treated or not with BCG (MAC-T and MAC-T-BCG respectivesly) alone or locally combined with NO inhibitors (E).
Immunohistochemical staining of FGF-2 was performed in s.c. MB49 tumors from mice treated with BCG, L-NAME or BCG plus L-NAME. Scale:
bar=100 um.
doi:10.1371/journal.pone.0013571.g006
BCG and Fibroblast Activation
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activated by BCG and the direct action on tumor cells would
reduce the risk of recurrence. The concentration of BCG used in
each instillation in patients, is approximately of 10
7 CFU/ml (total
volume 50 ml). We do not know the exact dosis that receive the
stroma, nevertheless, in our experiments we use 3610
6 CFU/ml,
which is the best dosis that induces the fibroblast proliferaton in
vitro, being one lower order than that used in the instillation of
patient. Thus, we speculate that the quantities of BCG we employ
in vitro are almost physiological.
It is known that bacterial stimuli are able to induce NO
production in MACs [27]. Here we showed that after BCG
treatment, RAW 264.7 and MACs-T were able to increase NO
levels in vitro and in vivo respectively and CM from RAW 264.7
treated in vitro with BCG induced fibroblast proliferation and
increased collagen I expression. Because of the involvement of NO
in various aspects of physiological and pathological processes,
NOS inhibitors have gained prominence in the mechanisms
involved in wound healing, angiogenesis and inflammatory
response to cytokines [28,29,30]. Since CM from MACs-T-
BCG-L-NAME induced the highest fibroblast proliferation rate,
we could speculate that in this cell population, inhibition of NO
induces the release of some soluble factors, able to increase
fibroblast proliferation and activation. Besides, we cannot discard
that NO inhibition may also modify the secretion pattern of these
soluble factors. To our knowledge, there are no reports showing
the interaction between MACs and fibroblast in bladder cancer.
However, in concordance with our results, using a pulmonary
tuberculosis model, it has been described enhanced proliferation of
pulmonary fibroblast by CM of alveolar macrophages stimulated
with BCG [31]. Concurrently, we observed concordance between
the effect of the in vivo treatment of bladder tumos and the in vitro
assay. A marked expression of collagen fibers and alpha-SMA was
observed in tumors treated with BCG, L-NAME and BCG plus L-
NAME, being the effect more pronounced with the combined
treatment.
The role of NO in dermal fibroblast proliferation has been
previously described by Chen et al [32], who suggested that
inhibition of dermal fibroblast proliferation by UV light, might be
related to the up-regulation of iNOS gene expression and thus to
NO over-secretion In agree with these results, we may suggest
that NO production is a negative regulator of fibroblast
proliferation and activation when BCG is used in bladder cancer
therapy.
Tumors and wounds share some components, such as the
inflammatory context [22]. However, while in wounds inflamma-
tion is transient, in tumors this process is perpetuated in time,
making this reversion, a goal for tumor growth control. In 1986,
Dvorak postulated the concept of ‘‘tumors are wounds that do not
heal’’ and hypothesized that the composition of the tumor stroma
resembles the granulation tissue of healing skin wound, which
suggests that epithelial tumors promote the formation of their
stroma by activating the wound healing response of the host
[22,33]. Based on this hypothesis, we generated a dorsal skin
wound assay, to evaluate the role of macrophages under different
treatments in a model where fibroblasts have a key function. We
evaluated the capacity of MACs-T-BCG to help in wound healing.
We observed that exogenous MACs-T accelerated the healing
process, but on the contrary MACs-T-BCG decreased healing rate
compared with MACs-T. However, in the presence of a NO
inhibitor, the wound closure was accelerated, suggesting that the
NO released by MACs-T-BCG delays the healing process. To
evaluate the role of endogenous NO of the host, L-NAME was
orally administered to wound-bearing mice, the wound closure
was significantly faster when MACs-T-BCG were placed in the
wounds. In summary, our results suggest that, besides the NO
released onto the wound by MACs-T-BCG, other cells producing
NO in wound-bearing mice play a negative role in the healing
process. The information related to NO activity in wound repair is
controversial. Some authors have shown that NO induces an
angiogenic process necessary for a good healing [29,34], whereas
others have demonstrated that apoptosis induced by NO is able to
inhibit wound healing [30]. On the basis of our results, we may
speculate that the NO generated by MACs-T-BCG or by the
remaining cancer cells can delay the tissue reorganization during
the BCG immunotherapy.
Divergent functions of growth factors, such as FGF-2 or TGF-
beta, in wound healing and cancer have also been reported. It is
well known that during the wound healing process, MACs secrete
FGF-2 and TGF-beta1 which influence fibroblast proliferation
[13]. Since in our model we observed that the RAW 264.7 cell line
decreased TGF-beta secretion under BCG treatment (data not
shown), we can discard this growth factor as a possible mediator of
the effects of BCG on fibroblasts proliferation On the other hand
we demostrated that RAW 264.7 activated by BCG produced
FGF-2, which was able to induce fibroblast proliferation. The
histological analyses from wounds treated with MACs-T-BCG
plus L-NAME or 1400W revealed an increase in FGF-2
expression compared with MACs-T. Besides, BCG and L-
NAME-treated tumors presented higher FGF-2 expression than
untreated ones. The exact role of FGF-2 is controversial, since its
function seems to depend on the relative concentration and the
degree of activation in the specific tissue [35]. It has been reported
that L-NAME inhibits the endothelial cell tube formation in
response to FGF-2 [36]. Thus, we could speculate that the
angiogenic activity in our model could be inhibited by L-NAME,
and that only the fibrotic activity would persist. Interestingly, it has
been reported that an anti-idiotypic strategy mimics the biological
activity of FGF-2, inhibiting the progression of an experimental
bladder cancer [37]. However, further experiments should be
performed to clarify the precise role of FGF-2 in response to BCG
in bladder cancer. Our present results seem to suggest that, at least
in part, this factor was involved in the mechanisms of bladder
cancer control by BCG.
In conclusion, as shows figure 7, our findings suggest that when
BCG is used as immunotherapy in bladder cancer, BCG targets
not only immune or tumor cells, but also fibroblasts either directly
and/or through activated MACs. We believe that NO produced
by MACs and tumor cells, is an undesired effect of BCG
immunotherapy and therefore, the possibility of modulating iNOS
activity concomitantly with conventional BCG therapy in patients
should be considered.
Materials and Methods
Cell Culture
NIH-3T3 (ATCC) cell line and macrophages RAW 264.7 were
maintained in DMEM (GibcoH). The murine bladder cancer cell
line MB49 was cultured in MEM (GibcoH). All cultured media
were supplemented with 2 mM L-glutamine, 80 ug/ml gentamy-
cin and 5-10% fetal calf serum (FCS) in a humidified atmosphere
with 5% CO2.
BCG
Living organisms of an attenuated strain of mycobacterium
tuberculosis, (Pasteur 1173 P2 strain, were obtained from Instituto
Nacional de Produccio ´n de Biolo ´gicos A.N.L.I.S. C.G. Malbra ´n,
Buenos Aires, Argentina.
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5610
3 NIH-3T3/100 ul were cultured in 96-well plates
(Greiner Labortechnik GmbH. Maybachstrabe 2, D-72636
Frickenhausen). After 24 h incubation, different concentrations
of BCG from 1.5 to 7.5610
6 CFU/ml were added, and cells were
cultured for 24 h. Cell viability was determined by the MTS assay
(Promega). To evaluate if MTS assay correlate with cell
proliferation, similar assays were made in 6 well dish and NIH-
3T3 cell proliferation were determined by cell counting with
Trypan Blue. To evaluate whether the MAPK or PI3K pathways
were involved in BCG induction, NIH-3T3 cells were treated with
BCG plus 10 and 20 mM of LY 294002 (Millipore) for 24 h or 10
and 50 uM of PD 98059 (Millipore) for 48 h. To evaluate NOS
inhibitor activity on fibroblast viability, similar experiments were
carried out in the presence of different concentrations of L-NAME
(N-nitro-L-arginine-methyl-ester, Sigma). In other series of
experiments 50% of conditioned media (CM), from peritoneal
MACs from different groups described before, or from RAW
264.7 cells treated with BCG, were added during 48 h and cell
viability was determined by MTS. When proliferation was
measured by
3(H)-thymidine incorporation, CM was preincubated
1 h with 10 mg/ml of the blocking monoclonal anti FGF-2
antibody (DB3), or normal mouse IgG as a control. Control was
carried out with exhausted culture media (from the same NIH-
3T3 cells). 0.5 ng/ml of FGF-2 was used as a positive control. After
2h ,1mCi
3(H)thymidine/well was added and cells were incubated
for 48 h. The assay was stopped with 50 ml/well of 6 M
guanidinium chloride. Cells were lysed by three freeze-thaw cycles.
The cellular DNA was collected on Whatman GFC filters using a
harvester (Cell Harvester 8, Nunc), fixed with 96% ethanol, air
dried and incorporated radioactivity was determined in the
presence of 1 ml of scintillation solution (OptiPhos Hifase 3) in a
liquidscintillationcounter(Packard1600 TR,CanberraCompany).
Peritoneal macrophages
Taking into account that in a mouse model the number of
intratumoral macrophages is very low and that BCG triggers
systemic effects being some of them correlated with response to
treatment [38], in this work, we have chosen to use peritoneal
macrophages since, the peritoneum is from where, we can obtain
more number of cells per mouse.
C57BL/6J male mice (approximately 8 weeks old), were
obtained from our Institute Animal Care Division. Animal care
was followed in accordance with the international procedure for
the Care and Use of Laboratory Animal. Protocols were approved
by the Institutional Review Board.
MB49 cells (5610
5 cells in 0.1 ml), were s.c. injected into the left
flank of syngeneic mice. BCG (6610
6 CFU/ml), was intratumo-
rally injected twice a week for twenty days starting 24 hs after
tumor cell inoculation. Control mice were equally injected with
saline solution. L-NAME (0.2 g/kg mouse), was added to drinking
water. After twenty days MACs were obtained by washing the
peritoneal cavity with cool PBS-EDTA 0.02%. MAC had been
purified from the peritoneal washes by plastic adhesion for 2 h.
For in vivo assay of wound repair, 10
6 MACs from each
experimental group were placed onto wounds, n=6.
Preparation of the Conditioned Media (CM)
RAW 264.7 cell line was treated in vitro with BCG
(36106 CFU/ml) or L-NAME (2 mM) and peritoneal MACs
were obtained from tumor-bearing mice treated in vivo with BCG
(66106 CFU/ml) or L-NAME (2 mM). After each treatment of
semiconfluent RAW 264.7 cells or peritoneal MACs monolayer
growing in 35 mm plates were extensively washed with PBS.
Serum-free medium (1 ml), was added and incubation was
continued for 24 hours. CM was harvested and the number of
cells in the remaining monolayer was quantified. CM samples
were aliquoted, stored at 80uC and used only once after thawing.
After the exhaustive washing no traces of BCG were observed.
NO production
NO production in MACs supernatants was determined after
24 h of BCG treatment either with or without the addition of L-
NAME in the case of RAW 264.7 cells and directly, from
peritoneal MACs of tumor bearing mice which had been treated
with L-NAME using the protocol as previously described [11].
Western blot assay
6610
5 NIH-3T3 cells were plated in 100-mm culture dishes.
When the monolayer reached 80% of confluence, the cultures were
treated with 3610
6 CFU/ml of BCG at the indicated times. Cells
weregentlywashedwithPBSandlysedusingproteinextractionlysis
buffer (50 mM Tris-HCl (pH 8.0); 100 mM NaCl; 1% Triton,
1 mM/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml
leupeptin and 10 mM EDTA/EGTA). Protein concentration was
determined by Bradford method according to the manufacturer’s
Figure 7. Combined therapy of BCG and L-NAME exerts an antitumoral effect through modulation of MACs and fibroblasts in the
tumor microenvironment. BCG directly induces fibroblast proliferation via MAPK and PI3K signaling pathways as well as alpha-SMA and collagen
expression. BCG induces in MACs the production of NO and soluble factors including FGF-2 which induce fibroblast proliferation. BCG therapy
increases collagen deposition and expression of alpha-SMA and FGF-2 in bladder tumors The treatment with L-NAME, improves the stimulation of
fibroblasts by BCG.
doi:10.1371/journal.pone.0013571.g007
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p-AKT or p-ERK and 80 mg for alpha-SMA, collagen I or FGF-2),
and analysed in 10% sodium dodecyl sulfate-polyacrylamide gel
(SDS-PAGE) and transferred onto a PVDF membrane. After
blotting, the membrane was incubated with primary antibody (p-
AKT, (sc-7985-R); AKT (sc-8312); p-ERK (sc-7383), ERK K (BD
Biociences 610124), (1,1000), collagen type I (sc-8784); alpha-SMA
(sc-53142) (1,200) or FGF-2 (1.25 ug/ml) developed by A. Baldi as
described [39]) and incubated with horseradish peroxidase-
conjugated secondary antibody (Millipore) (1,2000 dilution), for
1 h at room temperature. The blots were developed using the ECL
detection kit (GE Healthcare, USA), and exposed to X-ray film.
Bands were analysed in software. Then, membranes were stripped
and incubated over with ERK or AKT antibodies respectively or
beta-actin (Sigma, A5441) (1,20000 dilution), was used as a loading
control. In the WB corresponded to FGF-2, 20 ng of purified
murine FGF-2 was used as a positive control. Densitometric units of
p-AKT or p-ERK were relativized to the correspondent band of
AKTorERK. Densitometricunits ofcollagen,alpha-SMAorFGF-
2 were relativized to the correspondent band of beta-actin or
GAPDH. Values were referred as a fold change of control.
Immunofluorescence assay
NIH-3T3 cells growing in chamber slides in complete medium
were treated with BCG or CM from peritoneal MACs or from
RAW264.7 cells as described before. Subconfluent monolayers
were gently washed with cold saline buffer and processed for
immunofluorescence. Slides were fixed with formalin 4% in PBS
for 15 minutes and permeabilized. Nonspecific antibody binding
was blocked with Tween-20 0.1% plus 2% succinimidyl 4-
formylbenzoate in PBS for 60 minutes at room temperature.
Fixed cells were incubated overnight with rabbit polyclonal
antibody (1:100 dilution) anti-alpha-SMA (sc-53142), collagen I
(sc-8784) or FGF-2 (2.5 ug/ml). Rabbit IgG was used as isotype
control. Goat anti-rabbit IgG-fluorescein conjugate (ChemiconH;
1:150 dilution) in PBS, served as the secondary antibody. Nuclei
were counterstained with DAPI, slides were observed in an Nikon
Eclipse
TM E400 fluorescence microscope and photographed with
a CoolpixH 995 digital camera at 400 magnification.
Immunohistochemistry
Alpha-SMA and FGF-2 expression levels were histologically
determined in paraffin-embedded sections in s.c. MB49 tumors
from mice treated for 24 days and in wounds, by HRP
immunohistochemical technique. Specific antibodies to alpha-
SMA,(sc-53142, 1:100 dilution) and FGF-2 (2.5 ug/ml) were used.
Labelled streptavidin biotin (LSAB; Dako Cytomation, CA), at
first biotinylated link universal was appplied. In a negative
controls, primary antibody were omitted in each case. For
collagen deposition determination, Masson’s trichrome staining
was performed as previously described (Carson F.L: Histotech-
nology. A self-instructional test. ASCP Press, Chicago, 1990.)
Skin Wounds repair assay in vivo
6 to week old male C57BL/6J mice were anesthetized with an
intraperitoneal injection of a combination of 70 mg/kg ketamine
and 5 mg/kg xylazine, mice were and depilated in the dorsal zone.
A 3 mm-diameter circle wound, including the skin and panniculus
carnosus muscle were defined using scissors. The wounds were
photographed, and then 1610
6 peritoneal MACs resuspended in
33 ul of PBS-glicerol, 2 mM L-NAME, or 1 mM 1400 W
(Calbiochem), were placed onto the wound. The wound closure
was photographed every day one week. At 24 h some mice were
sacrificed, the wound was isolated, fixed and embedded in
paraffin. Using Image J software, up to four perpendicular
diameters (d) were measured. The surface of the wound was
calculated using the following formula: 3.14166(d/2)
2 and the
wound closure was calculated as the percentage of the initial
wound area at day zero. We performed a new set of experiments
where skin wounds were created in mice administered with L-
NAME (0.2 g/kg mouse) as described [11].
Ethics Statement
C57BL/6J male mice (approximately 8 weeks old), were
obtained from our Institute Animal Care Division. Animal care
was followed in accordance with the international procedure for
the Care and Use of Laboratory Animal. Protocols were approved
by the Institutional Review Board COMITE INSTITUCIONAL
DE CUIDADO Y USO DE ANIMALES DE LABORATORIO
‘‘CICUAL’’. Res (CD) 2079/07. Secretarı ´a de Ciencia y Te ´cnica
FACULTAD DE MEDICINA, U.B.A. Paraguay 2155, Buenos
Aires City, Argentina (C1121ABG).
Statistical analysis
Three independent experiments were carried out and only one
is shown. The results were expressed as the mean 6 SD of six
replicates per group. Statistically significant values were compared
using ANOVA and Bonferroni’s contrast by using Graph Pad
InStat statistical package (version 3.01). p-values lower than 0.05,
were considered statistically significant.
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